Patients who carry reduced-function or nonfunctional CYP2D6 alleles have been found to derive inferior therapeutic benefit from tamoxifen and thus are at increased risk of breast cancer recurrence [120] or have significantly shorter disease-free survival than non-carriers [121]. This evidence concerns the gene CYP2D6 and breast cancer.